Please wait while the transcript is being prepared...
0:00
Hello, everyone.
This is the second session about
the pharmaceutical industry
and environmental aspects.
My name is Radi Haloub,
I am an associate professor
and program leader for
Biotech and Pharmaceutical
Management at
UCL Global Business School
for Health in London.
0:19
In this session, I'm
going to talk about
the pharmaceutical industry
and the environmental aspects
on the changes on health systems
and how these changes will have
an impact on the
pharmaceutical business.
It is very important
to remember that
the environment will always
affect the industries,
not only pharmaceuticals
and biotech,
but because this is
a unique industry,
sometimes these changes
can be unpredicted,
very uncertain and
cannot be controlled.
For example, COVID-19 was
not predicted in 2019,
but it became a fact
and a challenge to
pharmaceutical and
biotech industries.
Also, the changes
that the governments
introduced in order
to accelerate
the registration of
the COVID vaccine
can be a case study to use
to speed up the adaptation
of healthcare environment
in the future.
1:13
In this slide, we look at
the firm in terms of who we are,
what is the purpose of the
existence of our business,
and what do we have in terms
of resources and competencies.
And the structure
and systems in place
that we have in this firm.
The first analysis
that we have to do
is to look at the
firm themselves
and look at the
representatives in
the pharmaceutical
and biotech industry,
and to see why we do exist
and how these are going to
affect us in the future.
I put there the strategy
is all about fit.
How this firm is going to
fit within the environment
and the uncontrolled changes
within the environment?
Of course, there are factors
relevant to the
speed of adaptation,
the ability of the firm
to change their resources
and to allocate competencies
in the right direction
based on the changes
within the environment.
But it's always the
question of who we are,
and what's the purpose,
and what do we
have in terms of resources and
competencies and the structure
we offered in the
pharmaceutical firm.
